Injectable Combination Therapies for the Management of Diabetes: A Guide for Health Care Decision Makers

• Release Date: March 1, 2017
• Expiration Date: September 30, 2018
• Estimated Time to Complete Activity: 0.5 hours
• Compatible with all modern browsers and mobile devices

DISTINGUISHED FACULTY

Vanita R. Aroda, MD Scientific Director, Physician Investigator MedStar Community Clinical Research Center Associate Professor of Medicine, Endocrinology, Diabetes, and Metabolism, Georgetown University School of Medicine, Click here for biography Jeffrey Dunn, PharmD, MBA Senior Vice President Chief Clinical Officer VRx/MagellanRx Click here for biography Edmund Pezalla, MD, MPH CEO Enlightenment Bioconsulting Click here for biography

TARGET AUDIENCE

• Health care decision makers (HCDMs) including physicians and pharmacists from MCOs, ACOs, IDNs, specialty pharmacy providers, and other health systems
• Policy administrators, quality managers, IT professionals, nurse practitioners, diabetes educators, care managers

Statement of Need/Program Overview
Diabetes mellitus is a chronic progressive disease affecting an estimated 30 million Americans—nearly one in every ten persons—and its prevalence continues to increase with 1.4 million Americans newly diagnosed each year. Patients with type 2 diabetes mellitus (T2DM) represent 90%-95% of cases. Diabetes is associated with elevated risk for complications such as kidney failure, blindness, and lower limb amputations, comorbidities including hypertension and dyslipidemia, and increased cardiovascular mortality all of which lead to increased medical costs and indirect costs from work-related absenteeism, reduced productivity, and premature mortality. This activity highlights opportunities for health care decision makers (HCDMs) to improve the management of T2DM for their health plan members by implementing and/or recommending evidence-based practice recommendations within the framework of published treatment guidelines and patient-centered care.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Assess emerging and recently approved insulin-based combination therapies for the treatment of T2DM and cite their clinical trial data
• Apply strategies to increase coordination of diabetes care among multidisciplinary teams within the managed care setting
• Review a patient-centered approach for T2DM management and improved adherence to treatment
• Recommend a benefit design strategy that payers can implement to improve clinical outcomes and the overall value of T2DM management

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

	Accreditation Statement  Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
MER designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0816-9999-17-080-H01-P. Your record of participation will be automatically uploaded to CPE Monitor.

Type of Activity
This activity is certified as Knowledge-based CPE.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides .5 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 0.5 contact hours.

DISCLOSURE OF CONFLICTS OF INTEREST
It is the policy of Medical Education Resources (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Novo Nordisk, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, Impact Education, LLC, and/or Novo Nordisk, Inc. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.For Pharmacists: Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.